Adaptimmune Therapeutics PLC (NAS:ADAP)

$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 161.16 Mil PE Ratio: 0 PB Ratio: 10.80 GF Score: 70/100

Q1 2024 Adaptimmune Therapeutics PLC Earnings Call Transcript
6 days ago

$1.24 (+7.83%)

Earnings
Full Year 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript
Mar 06, 2024

$1.71 (+17.12%)

Earnings
Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript
Nov 08, 2023

$0.5628 (-5.57%)

Earnings
Half Year 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 09, 2023

$0.85 (-1.16%)

Earnings
Adaptimmune Therapeutics PLC to Discuss Completion of Strategic Combination with TCR2 Call Transcript
Jun 02, 2023
Q1 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript
May 12, 2023

$1.37 (+0.74%)

Earnings
Adaptimmune Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Full Year 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript
Mar 06, 2023

$1.32 (-25.00%)

Earnings
Q3 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript
Nov 08, 2022

$2.08 (+25.30%)

Earnings
Adaptimmune Therapeutics PLC Corporate Call Transcript
Sep 09, 2022
Half Year 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 04, 2022

$2.32 (+19.59%)

Earnings
Q1 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript
May 09, 2022

$1.54 (-9.94%)

Earnings
Q4 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript
Mar 14, 2022

$1.82

Earnings
Adaptimmune Therapeutics PLC at Citi Immuno-Oncology Summit (Virtual) Transcript
Feb 17, 2022
Q3 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript
Nov 04, 2021

$5.25 (-4.02%)

Earnings
Adaptimmune Therapeutics PLC Strategic Collaboration with Genentech Inc Presentation Transcript
Sep 09, 2021
Q2 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 09, 2021

$3.45 (-1.15%)

Earnings
Q1 2021 Adaptimmune Therapeutics PLC Earnings Call Transcript
May 06, 2021

$4.9 (-4.30%)

Earnings
Q4 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript
Feb 25, 2021

$5.94 (-0.83%)

Earnings
Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Adaptimmune Therapeutics PLC Corporate Analyst Meeting Transcript
Nov 20, 2020
Q3 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript
Nov 05, 2020

$5.31 (+0.19%)

Earnings
Adaptimmune Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Adaptimmune Therapeutics PLC at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020
Q2 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 06, 2020

$8.06 (-7.57%)

Earnings
Q1 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript
May 14, 2020

$4.35 (-4.19%)

Earnings
Q4 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript
Feb 27, 2020

$3.66 (+4.27%)

Earnings
Full Year 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript
Nov 06, 2019

$0.92 (-16.36%)

Earnings
Q2 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript
Aug 01, 2019

$2.95 (-10.33%)

Earnings
Adaptimmune Therapeutics PLC to Provide Clinical and Business Update Call Transcript
May 06, 2019
Q4 2018 Adaptimmune Therapeutics PLC Earnings Call Transcript
Feb 27, 2019

$4.64 (-4.53%)

Earnings

Adaptimmune Therapeutics PLC Corporate Call Transcript

Sep 09, 2022 / 12:00PM GMT

Release Date Price: $1.92 (-5.88%)

Transcript

Adrian G. Rawcliffe

Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Good morning. I'm Adrian Rawcliffe, Adaptimmune's CEO, and thank you for joining us. I refer you to our disclaimer. More details can be found in the press release we issued earlier this morning. I'm delighted to be introducing this new data from our SURPASS trial and our plans for the SURPASS family of trials. This data set confirms the power of our SPEAR T-cells to make a difference for patients. It identifies multiple tumor types for further development, and it continues our leadership position making T cells effective against solid tumors.

But before we get into that, I want to provide a little background on Adaptimmune and our technology. For those of you who are perhaps less familiar with Adaptimmune, we engineer T cells to fight cancer, empowering a person's own immune system against their disease. Our unique technology platform enables us to enhance the affinity of T cell receptors, or TCRs. T cells use TCRs to see targets on cells. If a target is recognized as alien, the T cell will kill

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.